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Abstract
The purpose of the present study was to determine whether probiotic supplementation (Lactobacillus casei Shirota (LcS)) prevents diet-
induced insulin resistance in human subjects. A total of seventeen healthy subjects were randomised to either a probiotic (n 8) or a control
(n 9) group. The probiotic group consumed a LcS-fermented milk drink twice daily for 4 weeks, whereas the control group received no
supplementation. Subjects maintained their normal diet for the first 3 weeks of the study, after which they consumed a high-fat (65 % of
energy), high-energy (50 % increase in energy intake) diet for 7 d. Whole-body insulin sensitivity was assessed by an oral glucose tolerance
test conducted before and after overfeeding. Body mass increased by 0·6 (SE 0·2) kg in the control group (P,0·05) and by 0·3 (SE 0·2) kg
in the probiotic group (P.0·05). Fasting plasma glucose concentrations increased following 7 d of overeating (control group: 5·3 (SE 0·1)
v. 5·6 (SE 0·2) mmol/l before and after overfeeding, respectively, P,0·05), whereas fasting serum insulin concentrations were maintained
in both groups. Glucose AUC values increased by 10 % (from 817 (SE 45) to 899 (SE 39) mmol/l per 120 min, P,0·05) and whole-body
insulin sensitivity decreased by 27 % (from 5·3 (SE 1·4) to 3·9 (SE 0·9), P,0·05) in the control group, whereas normal insulin sensitivity
was maintained in the probiotic group (4·4 (SE 0·8) and 4·5 (SE 0·9) before and after overeating, respectively (P.0·05). These results suggest
that probiotic supplementation may be useful in the prevention of diet-induced metabolic diseases such as type 2 diabetes.
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Insulin resistance is a major characteristic of obesity and
type 2 diabetes. A number of metabolically active tissues
and several potential mechanisms have been implicated in
the pathophysiology of insulin resistance, such as impaired
GLUT4 translocation to the cell membrane and reduced
skeletal muscle glucose uptake(1), elevated hepatic glucose
production(2) and impaired b-cell function, which lead to
reduced insulin secretion(3). In addition to these well-described
defects, there is emerging evidence to suggest that changes
in the gut microbiota might also play an important role in the
development of human metabolic disease, through a mecha-
nism that is linked to increased gut permeability, metabolic
endotoxaemia and systemic low-grade inflammation(4–7).
A clear association has been demonstrated between
metabolic disease and compositional changes in the gut micro-
biota, with a lower abundance of Firmicutes and a higher
proportion of Bacteroidetes and Proteobacteria in type 2
diabetic patients when compared with non-diabetic controls(8).
Similar results have been found in rodent studies in which
insulin resistance is induced via short-term, high-fat, over-
feeding(7). In addition to altering the composition of the gut
microbiota, high-fat diets have been shown to elevate
systemic lipopolysaccharide (LPS) concentrations(9,10), whereas
selective modification of the gut microbiota, through pre-
biotic supplementation, has been shown to reduce high-fat
diet-induced metabolic endotoxaemia and lower intestinal
permeability in obese diabetic mice(6). Furthermore, probiotic
supplementation has been shown to improve glycaemic control
and reduce metabolic endotoxaemia in diet-induced obese
mice(11). Therefore, prebiotic and/or probiotic supplemen-
tation may be a useful strategy to improve metabolic health
and prevent diet-induced insulin resistance and type 2 diabetes
in humans.
Consumption of probiotic yogurt has already been shown
to reduce fasting blood glucose concentrations and glycosy-
lated Hb levels in type 2 diabetic patients(12), but whether or
not probiotics can also prevent diet-induced insulin resistance
in otherwise healthy subjects is not yet known. Therefore, we
tested the hypothesis that 4 weeks of supplementation with
probiotics (Lactobacillus casei Shirota (LcS)) would prevent
insulin resistance induced by short-term, high-fat, overfeeding
in healthy young males and females. In the present study,
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we provide novel evidence that probiotics preserve glycaemic
control and prevent insulin resistance during a dietary chal-
lenge consisting of severe lipid overload, suggesting that
probiotics might be useful in the fight against human meta-
bolic disease.
Methods
Subjects
A total of seventeen healthy subjects (fourteen males and
three females; Table 1) volunteered for the present study.
They were recruited from the student population and the
local community. No payments or other incentives were
made for participation. The sample size for the present exper-
iment was estimated based on pilot data from our laboratory
in which we observed a large decrease in insulin sensitivity
after short-term, high-fat, overfeeding. The inclusion criteria
required subjects to be physically active (exercising at least
three times per week for more than 30 min at a time),
non-smokers, free from cardiovascular or metabolic disease
and not taking any medication, weight stable for at least
6 months, and with a normal BMI (18·5–24·9 kg/m2). Subjects
were excluded from the study if they had taken any probiotic
or prebiotic supplements within the previous 3 months. Due
to the nature of the dietary intervention, vegetarians and
vegans were excluded from the study. The present study
was conducted according to the guidelines laid down in the
Declaration of Helsinki, and all procedures involving human
subjects were approved by the Loughborough University
Ethics Committee for Human Participants. Written informed
consent was obtained from all subjects.
Pre-testing/pre-screening
Subjects visited the laboratory 3 weeks before the start of the
study for an initial pre-screening, which included an assess-
ment of BMI and fasting plasma glucose and insulin levels.
General study design
After the initial pre-screening visit, subjects were randomly
assigned to one of the following two groups: control group
(n 9, seven males and two females); probiotic group (n 8,
seven males and one female). The probiotic that was used
in the present study was LcS (commercially available as the
fermented milk drink Yakult Light). Both groups maintained
their habitual food intake during the first 3 weeks of the
study (days 1–21); however, the probiotic group also con-
sumed 65 ml of Yakult Light twice each day. An oral glucose
tolerance test (OGTT) was performed on day 22 for the
assessment of baseline insulin sensitivity. After completing
the first OGTT, subjects were provided with a high-fat
(65 % energy), high-energy (approximately 50 % increase in
energy intake) diet for 7 d. The probiotic group continued to
consume 65 ml of Yakult Light twice throughout the 7 d over-
feeding period. We selected a 4-week LcS supplementation
period, as previous experiments have demonstrated that this
is sufficient to alter the composition of the gut microbiota
in humans(13–15). On day 29, both groups returned to the
laboratory for a second OGTT for the assessment of post-
overfeeding insulin sensitivity.
Experimental procedures
On the experimental days (days 22 and 29: OGTT), subjects
arrived at the laboratory in the morning (between 07·00
and 09·00 hours) after an overnight fast of at least 10 h. After
voiding and being weighed, a twenty-gauge Teflon catheter
(Venflon; Becton Dickinson) was inserted into an antecubital
vein of one arm to allow repeated blood sampling during
the 2 h OGTT. A fasted blood sample (10 ml; t ¼ 0) was
obtained before subjects ingested a 25 % glucose solution
(75 g of glucose dissolved in 300 ml of water). Additional
10 ml blood samples were obtained at 15, 30, 45, 60, 90 and
120 min after glucose ingestion. Blood samples were divided
equally between Vacutainer tubes containing either K2EDTA
or a clotting catalyst (Becton Dickinson) for separation of
plasma and serum, respectively. EDTA tubes were stored on
ice, whereas serum tubes were left at room temperature
until complete clotting had occurred. Blood tubes were then
centrifuged at 2300 g for 10 min (EDTA, 48C; serum 208C),
and the resulting plasma or serum was removed and stored
at 2208C until later analysis.
Diet records, analysis and compliance during overfeeding
Subjects were provided with standardised forms and digital
kitchen scales for the purpose of recording weighed food
Table 1. Physical characteristics of the study subjects before and after 7 d of overeating
(Mean values with their standard errors)
Control group
(n 9; seven males, two females)
Probiotic group
(n 8; seven males, one female)
Baseline Overfed Baseline Overfed
Mean SE Mean SE Mean SE Mean SE
Age (years) 24 2 – – 25 2 – –
Height (m) 1·72 0·02 – – 1·77 0·03 – –
Body mass (kg) 72·1 4·8 72·7* 4·8 73·4 2·3 73·7 2·4
BMI (kg/m2) 24·2 1·2 24·4* 1·2 23·5 0·6 23·6 0·7
* Mean value was significantly different from that at baseline (P,0·05).
High-fat feeding and insulin resistance 597
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
intake on 3 d each week during the pre-experimental period
(days 1–21). Subjects also received detailed written and
verbal instructions on how best to complete these records.
These records were then used for the assessment of habitual
energy intake and diet composition so that individualised
diets could be planned and prepared for the 7 d overfeeding
period. The analysis of diet records and planning of food
intake for the overfeeding period were performed using
WISP version 4.0 (Tinuviel Software). The overfeeding
period was designed to increase energy intake by 50 % com-
pared with habitual food intake and consisted of foods that
were predominantly high in fat (65 % of energy consumed
as fat). During the overfeeding period, all food was purchased
and prepared by the research team and then delivered to the
subjects. Subjects were instructed to eat everything that was
provided to them, not to eat any other additional foods, and
to return any unwanted food so that it could be weighed
and the diet values adjusted if necessary. All subjects were
informed about the importance of strict diet adherence, and
we were confident that the subjects were fully compliant
with the diet intervention.
Blood analysis
Plasma samples were analysed by commercially available spec-
trophotometric assays for the determination of glucose (Glucose
PAP; Horiba Medical) and TAG (Triglyceride PAP; Horiba Medi-
cal) concentrations using a semi-automatic analyser (Pentra 400;
Horiba Medical). The CV ranged between 0·4 and 0·8 % for
plasma samples with high (10·9 mmol/l, glucose ingestion)
and normal (4·7 mmol/l, fasted) glucose concentrations. The
CV ranged between 1·6 and 3·4 % for plasma samples with
normal (1·1 mmol/l) and low (0·5 mmol/l) TAG concentrations.
Serum insulin concentrations were analysed by an enzyme-
linked immunosorbent assay (ELISA EIA-2935; DRG Instru-
ments GmbH). The CV for serum insulin analysis was 3·0 %
for a mid-range sample (375 pmol/l, glucose ingestion).
Calculations
Plasma glucose and serum insulin concentrations obtained
from the OGTT were used to assess whole-body insulin sensi-
tivity using the Matsuda insulin sensitivity index (ISI):
ISI ¼ 10 000ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiðFPG £ FPIÞ £ ðmean OGTT insulin concentrationÞp
£ðmean OGTT glucose concentrationÞ;
where FPG is the fasting plasma glucose concentration; FPI is
the fasting plasma insulin concentration; and 10 000 represents
a constant that allows numbers ranging between 1 and 12. The
square root conversion is used to correct the non-linear distri-
bution of values(16).
AUC
The AUC was calculated using the trapezoidal rule with zero
as the baseline.
Statistical analysis
The primary outcome measurement was a change in insulin
sensitivity (determined from plasma glucose and serum insulin
concentrations during an OGTT). Secondary outcome
measurements were changes in body mass, BMI and fasting
plasma TAG concentrations. Data analysis was performed
using SPSS version 21.0 for Windows (SPSS, Inc.). Data are
presented as means with their standard errors. To compare
potential differences in metabolic responses to overfeeding,
a two-way (pre- v. post-overfeeding) repeated-measures
ANOVA was conducted with a between-subject variable
(control v. probiotic group) followed by post hoc analysis
where appropriate. The level of significance was set at P,0·05.
Results
Weight gain and BMI with overeating
By the end of the 7 d overfeeding period, subjects in the con-
trol group had gained a body mass of 0·6 (SE 0·2) kg (P,0·05),
whereas the increase in body mass for those in the probiotic
group was smaller and not significant (0·3 (SE 0·2) kg,
P.0·05). No significant changes in BMI occurred as a result
of 7 d of overeating. Data for body mass and BMI are summar-
ised in Table 1.
Fasting plasma substrates and serum insulin
Fasting plasma glucose concentrations increased following 7 d
of overeating (control group: 5·3 (SE 0·1) v. 5·6 (SE 0·2) mmol/l
before and after overfeeding, respectively, P,0·05), whereas
fasting serum insulin concentrations were well maintained
in both groups. Fasting plasma TAG concentrations were
decreased following overeating (both groups, P,0·05). Fast-
ing data summarised in Table 2 were obtained from the zero
time point (before glucose ingestion) of the OGTT that was
performed before and after overfeeding.
Energy intake and diet composition
Habitual energy intake and diet composition were similar
between the control and probiotic groups (Table 3). The
intentional overfeeding period increased energy intake by
51·9 and 51·3 % in the control and probiotic groups, respect-
ively (P,0·05). The majority of this additional energy was
provided by an increase in dietary fat intake.
Oral glucose tolerance test
The plasma glucose and serum insulin responses to an OGTT
before and after 7 d of overfeeding are shown in Fig. 1. In the
control group, overfeeding caused a 10 % increase in glucose
AUC values (from 817 (SE 45) to 899 (SE 39) mmol/l per
120 min, P,0·05; Fig. 1(a)), whereas no change was observed
in the probiotic group (baseline: 866 (SE 49) mmol/l per
120 min; overfed: 888 (SE 53) mmol/l per 120 min; Fig. 1(b)).
A similar trend was observed for insulin responses (Fig. 1(c)
and (d)), but did not reach significance.
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Insulin sensitivity
After 7 d of overfeeding, whole-body insulin sensitivity in the
control group was impaired by 27 % (decreased from 5·3
(SE 1·4) to 3·9 (SE 0·9), P,0·05), whereas no change in insulin
sensitivity was observed in the probiotic group (Fig. 2).
Discussion
The main finding of the present study was that high-fat over-
feeding decreased insulin sensitivity by approximately 27 % in
healthy young males and females; however, supplementation
with the LcS probiotic before and throughout the overfeeding
period preserved glycaemic control and maintained insulin
action. These results provide further indirect evidence that
compositional changes in the gut microbiota lead to the
development of human metabolic disease and that probiotic
supplementation could be useful in preventing insulin resist-
ance induced by excessive consumption of high-fat foods
(i.e. a Westernised diet).
Numerous rodent studies have reported that short-term (3 d
to 4 weeks) adherence to a high-fat diet induces insulin resist-
ance(17–23), and similar results have been reported in a small
number of recent human studies(2,24,25), because of which
we chose to adopt this model in the present study. Although
the underlying mechanisms for the development of insulin
resistance remain unclear, a popular theory is that excessive
consumption of high-fat foods can lead to the accumulation
of reactive intra-myocellular lipids, such as ceramide and
diacylglycerol, which inhibit insulin signalling (insulin/IRS-1/
PI3-K/AKT pathway) and impair GLUT4 translocation to the
cell membrane, thereby reducing skeletal muscle glucose
uptake(26–28). Another potential mechanism is systemic low-
grade inflammation, as the prevalence of insulin resistance is
associated with an increase in LPS (a component of the cell
wall of Gram-negative bacteria) concentrations in the
blood(29,30). Furthermore, in experimental models of meta-
bolic endotoxaemia, using intravenous or subcutaneous LPS
infusion, it has been found that LPS acts as a trigger for pro-
inflammatory cytokine production(4,31), which, in turn, leads
to impaired insulin action through increased serine phos-
phorylation of insulin receptor substrate-1(31,32). Interestingly,
the increase in systemic LPS levels that is associated with the
metabolic syndrome is thought to originate from the Gram-
negative bacteria living in the gut(5–7,10,30,33). Normally, the
intestinal epithelium would act as a physical barrier to prevent
LPS translocation into the circulation. However, reduced
expression of intestinal epithelial tight junction proteins (ZO-1
and occludin) and increased gut permeability (i.e. decreased
gut barrier function) have been observed in animal models of
insulin resistance and type 2 diabetes(5,6). This decrease in
gut barrier function may be causally linked to diet-induced
changes in the composition of the gut microbiota, as high-
fat diets have been shown to increase the ratio of Bacteroi-
detes (Gram-negative) to Firmicutes (Gram-positive) and
increase gut permeability that led to the development of
diabetes in mice(7). Furthermore, selectively increasing the
abundance of Bifidobacterium spp., through prebiotic
supplementation, has been shown to reduce intestinal
permeability in obese diabetic mice(6). In the context of the
Table 2. Fasting plasma substrate and serum insulin concentrations before and after 7 d of
overeating
(Mean values with their standard errors)
Control group
(n 9; seven males, two females)
Probiotic group
(n 8; seven males, one female)
Baseline Overfed Baseline Overfed
Mean SE Mean SE Mean SE Mean SE
Glucose (mmol/l) 5·3 0·1 5·6* 0·2 5·8 0·1 5·8 0·1
Insulin (pmol/l) 86 9 86 11 81 9 75 12
TAG (mmol/l) 1·4 0·3 0·9* 0·1 1·4 0·2 1·0* 0·2
* Mean value was significantly different from that at baseline (P,0·05).
Table 3. Daily energy intake and diet composition before and after 7 d of overeating
(Mean values with their standard errors)
Control group
(n 9; seven males, two females)
Probiotic group
(n 8; seven males, one female)
Baseline Overfed Baseline Overfed
Mean SE Mean SE Mean SE Mean SE
Energy (kJ) 9934 759 15 091* 1079 10 751 581 16 265* 865
Protein (g) 97 8 117* 9 103 6 127* 8
Carbohydrate (g) 292 17 213* 13 317 11 226* 15
Fat (g) 91 11 259* 11 103 12 281* 15
* Mean value was significantly different from that at baseline (P,0·05).
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present study, this tends to suggest that the ability of probiotic
supplementation to prevent high-fat diet-induced insulin
resistance is most probably due to the maintenance of a
favourable gut microbiota and preservation of gut barrier
function, although further mechanistic work will be necessary
to confirm this finding.
The main limitation of the present study was that we cannot
confirm whether the high-fat diet altered the composition of
the gut microbiota, impaired gut barrier function or led to
an increase in systemic inflammation, nor can we confirm
the impact of LcS probiotic supplementation on these physio-
logical outcomes. Although it was not possible to identify the
underlying mechanisms in the present study, we have dis-
cussed our observations and speculated upon the possible
causes in the context of what has already been shown in ani-
mals. It is also important to keep in mind that this was a
preliminary, proof-of-concept investigation into the efficacy
for probiotic supplementation to maintain human metabolic
health. Therefore, it was important to assess the changes in
whole-body insulin sensitivity (i.e. the primary outcome
measurement), and to confirm our experimental hypothesis,
before conducting the more costly and time-consuming
mechanistic experiments. In future studies, it will be nece-
ssary to perform faecal DNA analysis in order to determine
diet- and/or probiotic-induced changes in gut microbiota
composition, as well as to measure the markers of gut barrier
function and changes in systemic and tissue inflammation.
Nonetheless, the preliminary finding that 4 weeks of LcS
probiotic supplementation maintained glycaemic control and
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Fig. 2. Matsuda insulin sensitivity index calculated during an oral glucose
tolerance test conducted before and after 7 d of overeating for the
control and probiotic groups. Values are means, with their standard errors
represented by vertical bars (n 9, control group; n 8 probiotic group). * Mean
value was significantly different from that at baseline (P,0·05). , Baseline;
, overfed.
11(a) (b)
(c) (d)
10
9
8
7
6
5
4
3
700
600
500
400
300
200
100
S
er
u
m
 in
su
lin
 (
p
m
o
l/l
)
P
la
sm
a 
g
lu
co
se
 (
m
m
o
l/l
)
P
la
sm
a 
g
lu
co
se
 (
m
m
o
l/l
)
S
er
u
m
 in
su
lin
 (
p
m
o
l/l
)
0
700
600
500
400
300
200
100
0
0 15 30 45
Time (min)
60 90 120
0 15 30 45
Time (min)
60 90 120 0 15 30 45
Time (min)
60 90 120
11
10
9
8
7
6
5
4
3
0 15 30 45
Time (min)
60 90 120
Fig. 1. Plasma glucose ((a) control group and (b) probiotic group) and serum insulin ((c) control group and (d) probiotic group) concentrations during a 2 h oral
glucose tolerance test conducted before and after 7 d of overeating. Values are means, with their standard errors represented by vertical bars (n 9, control group;
n 8 probiotic group). , Baseline; , overfed.
C. J. Hulston et al.600
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
prevented insulin resistance during a dietary challenge that
consisted of severe lipid overload (approximately 270 g of
fat/d) suggests that diet-induced changes in the gut microbiota
are likely to play an important role in human metabolic
health and disease. Anti-diabetic properties of certain pro-
biotics have been reported in several rodent studies(11,34–37)
and in one human study(12). In the latter study, sixty-four
type 2 diabetic patients consumed either a probiotic yogurt
containing Lactobacillus acidophilus La5 and Bifidobacterium
lactis Bb12 or a placebo, probiotic-free, yogurt for 6 weeks.
The authors have reported a significant decrease in both
fasting blood glucose and glycosylated Hb concentrations as
well as an improvement in antioxidant status. We did not
find a reduction in fasting glucose or insulin concentrations
following probiotic supplementation, most probably because
of the fact that we tested healthy young subjects with
normal baseline values. However, the present results demon-
strate that regular consumption of LcS probiotics may offer
protection against the development of diet-induced insulin
resistance. Not all studies have reported metabolic health
benefits following LcS supplementation. Triplot et al.(38)
reported that 12 weeks of supplementation with LcS failed
to improve insulin sensitivity or enhance b-cell function in
subjects with the metabolic syndrome. The discrepancy
between their previous findings and the present study may
be related to the recruitment of a clinical population as
opposed to healthy volunteers. With this in mind, it is reason-
able to suggest that LcS probiotics could be used more
effectively in the prevention, rather than in the treatment, of
human metabolic disease.
We observed a significant decrease in fasting plasma TAG
concentrations after 7 d of overfeeding, which is consistent
with the findings of another very recent study(39). However,
the reduction in fasting plasma TAG concentrations is most
probably due to changes in the macronutrient composition
of the diet, rather than the amount of energy consumed.
Removing carbohydrate from the diet and replacing it with
an isoenergetic amount of fat has been shown to reduce
plasma TAG concentrations(40), whereas increasing the
amount of carbohydrate in the diet has been shown to have
the opposite effect and actually increases fasting plasma
TAG concentrations(41). This effect has been termed carbo-
hydrate-induced hypertriacylglycerolaemia(42). In the present
study, the amount of carbohydrate consumed during the over-
feeding period was reduced in both absolute and relative
terms when compared with the subject’s habitual food
intake (approximately 220 v. 305 g/d), and additional energy
intake was met through a large increase in the amount of fat
that was consumed, suggesting that the reduction in fasting
plasma TAG concentration may be related to the removal of
carbohydrate from the diet. Without the use of stable isotope
tracers, it is difficult to speculate on the reason for a reduction
in plasma TAG concentration after overfeeding; however, it
must be related to changes in TAG turnover: be it a decrease
in the synthesis rate, an increase in the clearance rate, or a
combination of both.
In conclusion, we have shown that probiotic supplemen-
tation has the potential to prevent high-fat diet-induced insulin
resistance in human subjects, and this warrants confirmation
in a larger, placebo-controlled study. Further mechanistic
studies are also necessary to confirm the underlying mechan-
ism for this effect.
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